Suppr超能文献

上皮性卵巢癌最佳肿瘤细胞减灭术不良候选者选择的临床及分子标准的叙述性综述

A Narrative Review of Clinical and Molecular Criteria for the Selection of Poor Candidates for Optimal Cytoreduction in Epithelial Ovarian Cancer.

作者信息

Pariza George, Mavrodin Carmen, Potorac Alina, Munteanu Octavian, Cîrstoiu Monica Mihaela

机构信息

Faculty of Medicine, "Carol Davila" University of Medicine and Pharmacy, 050474 Bucharest, Romania.

5th Department of General Surgery, Emergency Hospital Bucharest, 050098 Bucharest, Romania.

出版信息

Life (Basel). 2025 Aug 20;15(8):1318. doi: 10.3390/life15081318.

Abstract

The objective of this paper is to define "poor candidates" and to conduct an analysis of preoperative selection criteria, considering factors related to the patient, tumor burden, and histopathological characteristics, in the case of patients with advanced epithelial ovarian cancer (EOC) FIGO III-IV with a low probability of optimal cytoreduction. The authors of this narrative review conducted an analysis of articles published over a 20-year period (2005-2025), with the following selection criteria for the topics of the papers: advanced epithelial ovarian cancer (FIGOIII-IV), surgical indications in advanced ovarian cancer, poor candidates for surgery, and dependence between surgery and histopathologic and molecular type of EOC. They used using PubMed, Science Direct, and Scopus as databases. The results of the analysis were organized into three large chapters that grouped patient-related factors, tumor burden-specific factors, and histopathological criteria. The authors identify a series of criteria with a high risk of unfavorable postoperative evolution, which led to delayed chemotherapy treatment and suboptimal management. These criteria are related to the patient's field (ECOG > 3, Charlson Comorbidity Index (CCI) > 2, BMI > 25-30, hypoalbuminemia, hypokalemia), imaging or intraoperative factors predictive for residual tumor, and histopathological or genetic factors (presence of BRCA mutation favors optimal cytoreduction even in cases with high tumor burden; in the case of low-grade serous ovarian carcinoma, surgical intervention is recommended even if there are suboptimal resection criteria, accepting resection > 1 cm due to the poor response to specific chemotherapy treatment). Considering all these aspects, patient selection for primary debulking surgery (PDS) or NACT (neoadjuvant chemotherapy) and interval debulking surgery (IDS) should be conducted in oncological surgery centers highly specialized in gynecological neoplasms, thus ensuring an optimal therapeutic pathway for patients with EOC.

摘要

本文的目的是定义“不佳候选者”,并对术前选择标准进行分析,考虑与患者、肿瘤负荷和组织病理学特征相关的因素,针对国际妇产科联盟(FIGO)III-IV期晚期上皮性卵巢癌(EOC)且最佳肿瘤细胞减灭可能性较低的患者。这篇叙述性综述的作者对20年期间(2005年至2025年)发表的文章进行了分析,对文章主题有以下选择标准:晚期上皮性卵巢癌(FIGO III-IV)、晚期卵巢癌的手术指征、手术不佳候选者以及EOC手术与组织病理学和分子类型之间的相关性。他们使用PubMed、ScienceDirect和Scopus作为数据库。分析结果被整理成三大章,分别归类了与患者相关的因素、肿瘤负荷特异性因素和组织病理学标准。作者确定了一系列术后转归不佳风险较高的标准,这些标准导致化疗延迟和管理欠佳。这些标准与患者方面(东部肿瘤协作组体能状态评分(ECOG)>3、查尔森合并症指数(CCI)>2、体重指数(BMI)>25-30、低白蛋白血症、低钾血症)、预测残留肿瘤的影像学或术中因素以及组织病理学或遗传因素有关(BRCA突变的存在有利于即使在肿瘤负荷高的情况下实现最佳肿瘤细胞减灭;在低级别浆液性卵巢癌的情况下,即使存在切除不充分的标准,也建议进行手术干预,因对特定化疗治疗反应不佳而接受>1 cm的切除)。考虑到所有这些方面,对于原发性肿瘤细胞减灭术(PDS)或新辅助化疗(NACT)以及中间性肿瘤细胞减灭术(IDS)的患者选择,应在高度专业化的妇科肿瘤肿瘤外科中心进行,从而确保为EOC患者提供最佳治疗途径。

相似文献

2
Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.
Cochrane Database Syst Rev. 2022 Sep 26;9(9):CD015048. doi: 10.1002/14651858.CD015048.pub2.
3
Optimal primary surgical treatment for advanced epithelial ovarian cancer.
Cochrane Database Syst Rev. 2011 Aug 10;2011(8):CD007565. doi: 10.1002/14651858.CD007565.pub2.
5
Ultra-radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced epithelial ovarian cancer.
Cochrane Database Syst Rev. 2022 Aug 30;8(8):CD007697. doi: 10.1002/14651858.CD007697.pub3.
7
Surgical cytoreduction for recurrent epithelial ovarian cancer.
Cochrane Database Syst Rev. 2013 Feb 28;2013(2):CD008765. doi: 10.1002/14651858.CD008765.pub3.
8
Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer.
Cochrane Database Syst Rev. 2012 Aug 15;2012(8):CD005343. doi: 10.1002/14651858.CD005343.pub3.
10
Selective Advantage of NACT in Advanced Ovarian Cancer: A Retrospective Single-Centre Analysis.
Medicina (Kaunas). 2025 Aug 20;61(8):1493. doi: 10.3390/medicina61081493.

本文引用的文献

1
Controversies and clinical unknowns in the use of PARP inhibitors in ovarian cancer.
Ther Adv Med Oncol. 2025 Jun 14;17:17588359251343973. doi: 10.1177/17588359251343973. eCollection 2025.
2
Impact of molecular testing on the surgical management of advanced epithelial ovarian cancer.
Crit Rev Oncol Hematol. 2024 Oct;202:104469. doi: 10.1016/j.critrevonc.2024.104469. Epub 2024 Aug 5.
3
SEOM-GEICO clinical guideline on epithelial ovarian cancer (2023).
Clin Transl Oncol. 2024 Nov;26(11):2758-2770. doi: 10.1007/s12094-024-03531-3. Epub 2024 Jul 15.
4
Targeted Therapies in Low-Grade Serous Ovarian Cancers.
Curr Treat Options Oncol. 2024 Jul;25(7):854-868. doi: 10.1007/s11864-024-01205-4. Epub 2024 Jun 13.
5
Revisiting the Association of ECOG Performance Status With Clinical Outcomes in Diverse Patients With Cancer.
J Natl Compr Canc Netw. 2024 Apr 23;22(2 D):e237111. doi: 10.6004/jnccn.2023.7111.
9
PARP Inhibitors in Ovarian Cancer: A Review.
Target Oncol. 2023 Jul;18(4):471-503. doi: 10.1007/s11523-023-00970-w. Epub 2023 Jun 3.
10
Diagnostic and Therapeutic Pathway of Advanced Ovarian Cancer with Peritoneal Metastases.
Cancers (Basel). 2023 Jan 7;15(2):407. doi: 10.3390/cancers15020407.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验